Enhancement of Biological and Pharmacological Properties of an Encapsulated Polyphenol: Curcumin
- Witika, Bwalya A, Makoni, Pedzisai A, Matafwali, Scott K, Mweetwa, Larry L, Shandele, Ginnethon C, Walker, Roderick B
- Authors: Witika, Bwalya A , Makoni, Pedzisai A , Matafwali, Scott K , Mweetwa, Larry L , Shandele, Ginnethon C , Walker, Roderick B
- Date: 2021
- Subjects: To be catalogued
- Language: English
- Type: text , article
- Identifier: http://hdl.handle.net/10962/183161 , vital:43917 , xlink:href="https://doi.org/10.3390/molecules26144244"
- Description: There is a dearth of natural remedies available for the treatment of an increasing number of diseases facing mankind. Natural products may provide an opportunity to produce formulations and therapeutic solutions to address this shortage. Curcumin (CUR), diferuloylmethane; I,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione is the major pigment in turmeric powder which has been reported to exhibit a number of health benefits including, antibacterial, antiviral, anti-cancer, anti-inflammatory and anti-oxidant properties. In this review, the authors attempt to highlight the biological and pharmacological properties of CUR in addition to emphasizing aspects relating to the biosynthesis, encapsulation and therapeutic effects of the compound. The information contained in this review was generated by considering published information in which evidence of enhanced biological and pharmacological properties of nano-encapsulated CUR was reported. CUR has contributed to a significant improvement in melanoma, breast, lung, gastro-intestinal, and genito-urinary cancer therapy. We highlight the impact of nano-encapsulated CUR for efficient inhibition of cell proliferation, even at low concentrations compared to the free CUR when considering anti-proliferation. Furthermore nano-encapsulated CUR exhibited bioactive properties, exerted cytotoxic and anti-oxidant effects by acting on endogenous and cholinergic anti-oxidant systems. CUR was reported to block Hepatitis C virus (HCV) entry into hepatic cells, inhibit MRSA proliferation, enhance wound healing and reduce bacterial load. Nano-encapsulated CUR has also shown bioactive properties when acting on antioxidant systems (endogenous and cholinergic). Future research is necessary and must focus on investigation of encapsulated CUR nano-particles in different models of human pathology.
- Full Text:
- Date Issued: 2021
- Authors: Witika, Bwalya A , Makoni, Pedzisai A , Matafwali, Scott K , Mweetwa, Larry L , Shandele, Ginnethon C , Walker, Roderick B
- Date: 2021
- Subjects: To be catalogued
- Language: English
- Type: text , article
- Identifier: http://hdl.handle.net/10962/183161 , vital:43917 , xlink:href="https://doi.org/10.3390/molecules26144244"
- Description: There is a dearth of natural remedies available for the treatment of an increasing number of diseases facing mankind. Natural products may provide an opportunity to produce formulations and therapeutic solutions to address this shortage. Curcumin (CUR), diferuloylmethane; I,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione is the major pigment in turmeric powder which has been reported to exhibit a number of health benefits including, antibacterial, antiviral, anti-cancer, anti-inflammatory and anti-oxidant properties. In this review, the authors attempt to highlight the biological and pharmacological properties of CUR in addition to emphasizing aspects relating to the biosynthesis, encapsulation and therapeutic effects of the compound. The information contained in this review was generated by considering published information in which evidence of enhanced biological and pharmacological properties of nano-encapsulated CUR was reported. CUR has contributed to a significant improvement in melanoma, breast, lung, gastro-intestinal, and genito-urinary cancer therapy. We highlight the impact of nano-encapsulated CUR for efficient inhibition of cell proliferation, even at low concentrations compared to the free CUR when considering anti-proliferation. Furthermore nano-encapsulated CUR exhibited bioactive properties, exerted cytotoxic and anti-oxidant effects by acting on endogenous and cholinergic anti-oxidant systems. CUR was reported to block Hepatitis C virus (HCV) entry into hepatic cells, inhibit MRSA proliferation, enhance wound healing and reduce bacterial load. Nano-encapsulated CUR has also shown bioactive properties when acting on antioxidant systems (endogenous and cholinergic). Future research is necessary and must focus on investigation of encapsulated CUR nano-particles in different models of human pathology.
- Full Text:
- Date Issued: 2021
Muco-adhesive clarithromycin-loaded nanostructured lipid carriers for ocular delivery: Formulation, characterization, cytotoxicity and stability
- Makoni, Pedzisai A, Khamanga, Sandile M, Walker, Roderick B
- Authors: Makoni, Pedzisai A , Khamanga, Sandile M , Walker, Roderick B
- Date: 2021
- Subjects: To be catalogued
- Language: English
- Type: text , article
- Identifier: http://hdl.handle.net/10962/183150 , vital:43916 , xlink:href="https://doi.org/10.1016/j.jddst.2020.102171"
- Description: Topical ophthalmic formulations are the preferred approach to treat the anterior segment of the eye as it is a non-invasive therapeutic approach. The ocular bioavailability of drugs is generally limited, due to the presence of impervious anatomical barriers and low residence time and contact with the target tissue. Optimization of clarithromycin-loaded nanostructured lipid carriers using Design of Experiments was undertaken. Manufacture of nanostructured lipid carriers was achieved using hot emulsification ultrasonication. Formulation and process parameters were successfully identified following screening and subsequently optimized using Tween® 20, as a stabilizer. Muco-adhesive properties that could potentially increase ocular residence time, in vitro clarithromycin release and cytotoxicity against HeLa cells were evaluated. Short term stability studies of the optimized lipidic formulations was assessed at 4 °C and 22 °C. The optimized formulation exhibited muco-adhesive properties under stationary conditions assessed using Laser Doppler Anemometry, sustained release of API over 24 h under in vitro conditions. In vitro cytotoxicity studies revealed that the NLC were less cytotoxic to HeLa cells in comparison to pure API. The results suggest that the optimized carriers may have the potential to enhance precorneal retention, increase ocular availability and permit dose reduction or permit use of a longer dosing frequency.
- Full Text:
- Date Issued: 2021
- Authors: Makoni, Pedzisai A , Khamanga, Sandile M , Walker, Roderick B
- Date: 2021
- Subjects: To be catalogued
- Language: English
- Type: text , article
- Identifier: http://hdl.handle.net/10962/183150 , vital:43916 , xlink:href="https://doi.org/10.1016/j.jddst.2020.102171"
- Description: Topical ophthalmic formulations are the preferred approach to treat the anterior segment of the eye as it is a non-invasive therapeutic approach. The ocular bioavailability of drugs is generally limited, due to the presence of impervious anatomical barriers and low residence time and contact with the target tissue. Optimization of clarithromycin-loaded nanostructured lipid carriers using Design of Experiments was undertaken. Manufacture of nanostructured lipid carriers was achieved using hot emulsification ultrasonication. Formulation and process parameters were successfully identified following screening and subsequently optimized using Tween® 20, as a stabilizer. Muco-adhesive properties that could potentially increase ocular residence time, in vitro clarithromycin release and cytotoxicity against HeLa cells were evaluated. Short term stability studies of the optimized lipidic formulations was assessed at 4 °C and 22 °C. The optimized formulation exhibited muco-adhesive properties under stationary conditions assessed using Laser Doppler Anemometry, sustained release of API over 24 h under in vitro conditions. In vitro cytotoxicity studies revealed that the NLC were less cytotoxic to HeLa cells in comparison to pure API. The results suggest that the optimized carriers may have the potential to enhance precorneal retention, increase ocular availability and permit dose reduction or permit use of a longer dosing frequency.
- Full Text:
- Date Issued: 2021
- «
- ‹
- 1
- ›
- »